Vahid Iranpur

Dr. Vahid Iranpur

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
EMElham Mahdevar
Elham Mahdevar
ASAshkan Safavi
Ashkan Safavi
AAArdavan Abiri
Ardavan Abiri
AKAmirhosein Kefayat
Amirhosein Kefayat
SHSeyed Hossein Hejazi
Seyed Hossein Hejazi
VIVahid Iranpur
Vahid Iranpur
Recently, cancer immunotherapy has gained lots of attention to replace the current chemoradiation approaches and multi-epitope cancer vaccines are manifesting as the next generation of cancer immunotherapy. Therefore, in this study, we used multiple immunoinformatics approaches along with other computational approaches to design a novel multi-epitope vaccine against breast cancer. The most immunogenic regions of the BORIS cancer-testis antigen were selected according to the binding affinity to MHC-I and II molecules as well as containing multiple cytotoxic T lymphocyte (CTL) epitopes by multiple immunoinformatics servers. The selected regions were linked together by GPGPG linker. Also, a T helper epitope (PADRE) and the TLR-4/MD-2 agonist (L7/L12 ribosomal protein from mycobacterium) were incorporated by A(EAAAK)3A linker to form the final vaccine construct. Then, its physicochemical properties, cleavage sites, TAP transport efficiency, B cell epitopes, IFN-γ inducing epitopes and population coverage were predicted. The final vaccine construct was reverse translated, codon-optimized and inserted into pcDNA3.1 to form the DNA vaccine. The final vaccine construct was a stable, immunogenic and non-allergenic protein that contained numerous CTL epitopes, IFN-γ inducing epitopes and several linear and conformational B cell epitopes. Also, the final vaccine construct formed stable and significant interactions with TLR-4/MD-2 complex according to molecular docking and dynamics simulations. Moreover, its world population coverage for HLA-I and HLA-II were about 93% and 96%, respectively. Taking together, these preliminary results can be used as an appropriate platform for further experimental investigations. Communicated by Ramaswamy H. Sarma

1 May 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
VIVahid Iranpur
Vahid Iranpur
MMMohammad Hossein Modarressi
Mohammad Hossein Modarressi
PRPooneh Rahimi
Pooneh Rahimi
ABAzam Bolhassani
Azam Bolhassani
EAEhsan Arefian
Ehsan Arefian
RVRouhollah Vahabpour
Rouhollah Vahabpour

1 November 2019 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
GRGhassem Rezaei
Ghassem Rezaei
SDSeyed Mojtaba Daghighi
Seyed Mojtaba Daghighi
MRMohammad Raoufi
Mohammad Raoufi
MEMehdi Esfandyari-Manesh
Mehdi Esfandyari-Manesh
MRMahban Rahimifard
Mahban Rahimifard
RDRassoul Dinarvand
Rassoul Dinarvand

29 November 2018 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PRP Rahimi
P Rahimi
VIVahid Iranpur
Vahid Iranpur
SKS Kamalzare
S Kamalzare
FSF SajadianFard
F SajadianFard
RVR Vahabpour
R Vahabpour
RZR Zabihollahi
R Zabihollahi

1 May 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKSara Kamalzare
Sara Kamalzare
VIVahid Iranpur
Vahid Iranpur
FTFarnaz Sadat Mirzazadeh Tekie
Farnaz Sadat Mirzazadeh Tekie
MHMaliheh Hajiramezanali
Maliheh Hajiramezanali
FRFarhad Riazi-Rad
Farhad Riazi-Rad
FAFatemeh Atyabi
Fatemeh Atyabi

28 January 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
PRPooneh Rahimi
Pooneh Rahimi
HSHeidar Sharafi
Heidar Sharafi
GBGolnaz Bahramali
Golnaz Bahramali
FSFaridehSadat SajadianFard
FaridehSadat SajadianFard
NANafiseh Sadat Asadi
Nafiseh Sadat Asadi
SMSeyedeh Zahra Moravej
Seyedeh Zahra Moravej
Background: Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs). NS5A and NS5B RASs can occur in patients with HCV infection naturally and before exposure to DAAs.Objectives: This study aimed to evaluate naturally-occurring NS5A and NS5B RASs in Iranian patients with HCV genotype 1a (HCV-1a) and -3a infections.Methods: In this cross-sectional study, viral RNA was extracted from serum specimens. NS5A and NS5B regions were amplified using RT-PCR followed by DNA sequencing. The results of nucleotide sequences were aligned against reference sequences of HCV-1a and -3a and the amino acid substitutions were analyzed using geno2pheno [hcv] web application.Results: Among 135 patients with hepatitis C, NS5A amino acid substitutions/RASs were identified in 26.4% and 15.9% of patients with HCV-1a and -3a infections, respectively. The identified amino acid substitutions/RASs in the NS5A region of patients with HCV-1a infection were M28T/V/I 11.1%, Q30R/H 4.2%, L31M 1.4%, and H58Y/P/C/D/Q/S/T 16.7%. Y93H substitution was not found in HCV-1a sequences. In patients with HCV-3a infection, NS5A amino acid substitutions/RASs were A30T/K 9.5%, L31F 1.6%, P58S/T/C 3.2%, Y93H 3.2%, and Y93N 3.2%. No resistance substitutions were identified in NS5B sequences from patients with HCV-1a and -3a infections.Conclusion: In this study, baseline amino acid substitutions/RASs were only identified in the NS5A region in Iranian patients with HCV-1a and -3a infections, and the prevalence of these amino acid substitutions/RASs were in accordance with similar studies. There were no RASs in the HCV-1a and -3a NS5B region.